Answers are grounded in this paper and cite their sources.
Despite achieving complete or partial remission after the initial glomerulonephritis (GN) episode, patients remain at increased risk for the subsequent development and progression of chronic kidney disease (CKD). Post-GN is a unique CKD entity with clinical phenotypes driven by both disease-specific modifiers and general CKD pathways leading to progressive kidney decline. To minimize progressive renal dysfunction, CKD must be identified and treated in the specific GN context – with distinct dimensions compared to “generic” CKD. In this review, we define post-GN CKD and its phenotypic subtypes, discuss current management, and highlight emerging interventions. Current practice uses serum markers of glomerular filtration, urine protein quantification, and, as indicated, serologic testing and kidney biopsy to identify and risk stratify post-GN CKD subtypes. Core interventions include lifestyle modifications and achieving normotension. In addition to renin–angiotensin–aldosterone inhibition, sodium-glucose co-transporter-2 inhibitors have robust utility in post-GN patients. We discuss how novel targets including endothelin-receptor antagonists, non-steroidal mineralocorticoid receptor blockers, aldosterone synthase inhibitors, and incretin analogs can be tailored to post-GN CKD phenotypes. Finally, we highlight emerging advances including novel serum and urinary biomarkers of kidney injury, genomic and prognostic serologic testing, functional kidney imaging, and artificial intelligence–based machine-learning approaches that detect patients with early kidney dysfunction at heightened risk for rapid progression. These strategies aim to extend glomerular longevity, slow CKD progression, and empower personalized care.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: